SciMed Biotech Podcast with Shubhranshu Gupta

Shubhranshu Gupta, CEO and Founder of Immumem Therapeutics

Why immune memory could be the key to beating solid tumors

In this episode of the SciMed Biotech Podcast, Dr. Shubhranshu Gupta, CEO/CSO and Founder of Immumem Therapeutics, shares how his team is engineering immune memory into TN/NK cell therapies to tackle some of the toughest solid tumors with high relapse rates. We dive into why most cell therapies struggle with tumor penetration, persistence, and relapse—and how Immumem is training immune cells to overcome the tumor microenvironment and ECM barriers. Shubhranshu also breaks down how Immumem uses iPSC-derived cells to enable scalable, off-the-shelf therapies. The conversation closes with how machine learning is being used to bridge ex vivo results with predicted in vivo efficacy as the platform moves toward the clinic.